Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates.
about
Akt-and CREB-mediated prostate cancer cell proliferation inhibition by Nexrutine, a Phellodendron amurense extractEstrogen-Related Receptors in Breast Cancer and Prostate CancerExogenous hormonal regulation in breast cancer cells by phytoestrogens and endocrine disruptorsNetwork-based relating pharmacological and genomic spaces for drug target identificationPterostilbene-isothiocyanate conjugate suppresses growth of prostate cancer cells irrespective of androgen receptor statusAssociation of variants in estrogen-related pathway genes with prostate cancer risk.Sex hormones induce direct epithelial and inflammation-mediated oxidative/nitrosative stress that favors prostatic carcinogenesis in the noble rat.Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.Xenoestrogens regulate the activity of arginine methyltransferases.Oestrogens and spermatogenesis.Anticancer activities of genistein-topotecan combination in prostate cancer cells.PSA Decrease with Fulvestrant Acetate in a Hormone-Resistant Metastatic Prostate Cancer Patient: A Case ReportSafety and tolerability of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN).Estrogen receptors in prostate development and cancerToremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy.Molecular Basis of Steroid Action in the Prostate.ICI 182,780-regulated gene expression in DU145 prostate cancer cells is mediated by estrogen receptor-beta/NFkappaB crosstalk.Estrogen action and prostate cancer.Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study.Estrogens and prostate cancer: etiology, mediators, prevention, and management.Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention TrialAndrogens and estrogens in benign prostatic hyperplasia: past, present and future.Apigenin suppresses cancer cell growth through ERbeta.Chronic resveratrol treatment restores vascular responsiveness of cerebral arterioles in type 1 diabetic rats.Consumption of high ω-3 fatty acid diet suppressed prostate tumorigenesis in C3(1) Tag mice.Genistein increases estrogen receptor beta expression in prostate cancer via reducing its promoter methylation.Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies.Estrogen Exhibits a Biphasic Effect on Prostate Tumor Growth through the Estrogen Receptor β-KLF5 Pathway.The role of estrogens and estrogen receptors in normal prostate growth and disease.The role of estrogens in prostate carcinogenesis: a rationale for chemoprevention.Linking DNA Damage and Hormone Signaling Pathways in Cancer.Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies.Induction of proinflammatory response in prostate cancer epithelial cells by activated macrophages.Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivoEtiopathogenesis of benign prostatic hypeprlasia.Risks and benefits of dietary isoflavones for cancer.Combating malaria with plant molecules: a brief update.Circulating steroid hormones in prostate carcinogenesis. Part 2: Estrogens.Effects of Resveratrol on p66Shc phosphorylation in cultured prostate cells.Estrogen and estrogen receptor alpha promotes malignancy and osteoblastic tumorigenesis in prostate cancer.
P2860
Q24676177-1D709FDF-6A0B-435B-A55E-A1643A8BA757Q28084030-A613ADE5-A1E1-4E3E-9C7D-A1E455CB2ED3Q28393495-BDBA3E9A-6256-4D0F-B837-9FCC5D907188Q28474912-3B370BB2-C912-4BC5-A459-08463BF09DF8Q28541923-7426E424-2C60-4B0A-B1CF-C6A53D2F594EQ30532192-A332C737-9B22-443D-A88F-DC5E02807C85Q33295021-453B11F1-4B85-4CE4-B8D7-62C119A688B5Q33763973-1BA75215-A0DA-497E-897A-DF4D79EE5A4FQ33796036-CD91A0DF-CC78-4539-887C-3C515F98B876Q33856966-E99E3AF8-F8E1-4B84-833C-1BF58F8AF48DQ33985939-593A0597-1C27-48AD-BCB2-6A48F7110120Q34054729-2869C513-0E81-42A5-9CF1-BF75671370F9Q34323757-CD10B452-B25A-4CD3-BBB8-C9686F615684Q34448194-F01800E1-CBAE-4934-9646-5255A0991878Q34497901-9CBAE71B-2945-4A38-8486-FC980AEE9693Q35024939-2DFA2973-C3A7-4D15-91B8-1F5D2CC9E8DEQ35081520-59CFA3FA-79B4-46A5-BBEE-9EE085896BCAQ35099011-B8B5AA46-A032-4A37-904C-4D3D38438156Q35116362-13EB3E11-1A5C-4547-9EEE-99A361D55B58Q35196710-BC025F7C-216B-4573-84D2-B166F1EC5988Q35230322-88443587-F6F6-4ACB-B26C-43CBF1B78B30Q35231660-B1047711-6AF9-4B35-8E9D-7A6CBF150933Q35249798-8124EA66-61EA-450F-8860-3EF0317E9FABQ35314875-7FC7B022-42B5-4E17-9219-614E589F808DQ35747328-3C8BCEC4-F013-4C73-BEA9-BA0BE1C90DE9Q35850489-B674BA0C-9A6C-4896-9FAE-14DEA215265DQ36272854-EE18DEE8-30CD-4A49-A406-2A3A0FA5B7C3Q36434014-2DF2796D-2849-4718-B947-FD8E7B468FB2Q36488068-325006B1-28DB-457C-B032-2833DA7DDD54Q36598404-2525DBFB-C7E6-499C-A648-2FF02291E716Q36730819-A71509D0-70DE-4C7D-8EDB-41E6D9CD7A30Q36860976-8AB2E07E-21D6-4FE6-A4B5-FAB71F186E60Q37199013-2DB7CF7F-AE4C-4647-B516-2BFEDC5F5110Q37294641-8165DC8B-892C-4EBB-8D6E-7AB608E98DBDQ37625720-606959E4-0B42-4306-B3AC-2765EACCC251Q37857841-E9E7CC3C-3FD8-4899-B333-BB7F081C529CQ38155893-1FEFD938-38C9-401D-9DD7-DDB753E1D11BQ38471556-ABDDCDD6-43A3-4ED4-A0A9-F781A169C065Q38780934-82795B13-C682-4984-9628-E10C70C8D2CBQ38819069-E5861F30-B780-4870-B106-1BC84064A866
P2860
Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Estrogens and anti-estrogens: ...... nd new therapeutic candidates.
@ast
Estrogens and anti-estrogens: ...... nd new therapeutic candidates.
@en
type
label
Estrogens and anti-estrogens: ...... nd new therapeutic candidates.
@ast
Estrogens and anti-estrogens: ...... nd new therapeutic candidates.
@en
prefLabel
Estrogens and anti-estrogens: ...... nd new therapeutic candidates.
@ast
Estrogens and anti-estrogens: ...... nd new therapeutic candidates.
@en
P2860
P356
P1476
Estrogens and anti-estrogens: ...... nd new therapeutic candidates.
@en
P2093
Shuk-Mei Ho
P2860
P304
P356
10.1002/JCB.10759
P577
2004-02-01T00:00:00Z